Lilly's Weight-Loss Drug Launch Drives Hang Seng Healthcare ETF (159892) to Trade at Sustained Premium with Over 1% Gain

Major Breakthrough in Weight Loss Drugs! Eli Lilly's weight loss drug Zepbound launches in the U.S., with a price tag of $1,059.87 for six doses, approximately 20% lower than the cost of Novo Nordisk's weight loss drug Wegovy.

The concept of weight-loss drugs emerged in the second half of the year, strongly driving the recovery of the pharmaceutical sector. Previously, GLP-1 drugs were even selected for the 2023 Top Ten News list by a subsidiary journal of *Nature*. With recent catalysts such as new drug launches, the momentum is expected to continue.

After two days of adjustment, on December 6, 2023, Wuxi Biologics slightly increased, and the Hang Seng Medical ETF (159892) continued to trade at a premium during the session. SihuanPharm,BeOne Medicines、PharmaronA slight increase. After the recent index adjustment takes effect, BeOne Medicines tops the weight rankings.

From the overseas environment perspective, the end of the U.S. interest rate hike is approaching, the financing environment is improving, liquidity pressure in the secondary market has eased, and coupled with the recent continuous sharp declines, pessimistic expectations have been largely reflected. The pharmaceuticals sector is expected to begin a rebound.

Relevant ETFs: Hang Seng Medicine ETF (159892), Biotechnology ETF (516500), Pharmaceutical Health ETF (510660), Medical Device ETF (Pending Listing: 562600).